Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart

Financials

Date Filing Description Download
12/05/16 4 Statement of Changes in Beneficial Ownership
12/05/16 4 Statement of Changes in Beneficial Ownership
12/05/16 4 Statement of Changes in Beneficial Ownership
12/05/16 4 Statement of Changes in Beneficial Ownership

Stock Quote

ACOR (Common Stock) $ 21.20 +0.70 (+3.42%) Volume: 439,312 MORE December 8, 2016

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.